MediWound Ltd. Stock News

Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30

MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 7.04% and 57.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12.33% and 39.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology BridgeBio Pharma Inc 

MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs).  The study met its primary and secondary endpoin

YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and r

Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds

YAVNE, Israel, March 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective,

Primary Endpoint Met with Highly Statistically Significant ResultsFinal Data Readout Expected in Second Quarter of 2022

MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2021 Results - Earnings Call Transcript

MediWound (MDWD) delivered earnings and revenue surprises of 6.25% and 2.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AbbVie's Rinvoq Gets Label Expansion To Treat Ulcerative Colitis AbbVie, Inc. (NYSE: ABBV) announced 

MediWound (NASDAQ: MDWD ) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings MediWound reported in-line EPS of $-0.15 versus an estimate of $-0.15. Revenue was … Full story available on Benzinga.com

MediWound press release (MDWD): Q4 GAAP EPS of -$0.15 in-line.Revenue of $5.49M (-18.1% Y/Y) misses by $0.05M.